Daiichinkyo Co (TSE:4568) Gross-Profit-to-Asset % : 38.50% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Daiichinkyo Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was 円1,295,428 Mil. Daiichinkyo Co's average Total Assets over the quarter that ended in Mar. 2024 was 円3,365,040 Mil. Therefore, Daiichinkyo Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 38.50%.

Daiichinkyo Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Daiichinkyo Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Gross-Profit-to-Asset % Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

30.45

29.79

32.11

38.68

39.74

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															36.56	40.14	42.66	43.88	38.50

Competitive Comparison of Daiichinkyo Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Gross-Profit-to-Asset % falls into.

Daiichinkyo Co Gross-Profit-to-Asset % Calculation

Daiichinkyo Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2024 )	/	( (Total Assets (A: Mar. 2023 )	+	Total Assets (A: Mar. 2024 ))	/ count )
	=	1186366	/	( (2508889	+	3461135)	/ 2 )
	=	1186366	/	2985012
	=	39.74 %

Daiichinkyo Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	1295428	/	( (3268945	+	3461135)	/ 2 )
	=	1295428	/	3365040
	=	38.50 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Daiichinkyo Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (TSE:4568) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines